PubMed

Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice.

Cha DR, Zhang X, Zhang Y, Wu J, Su D, Han JY, Fang X, Yu B, Breyer MD, Guan Y.

Diabetes. 2007 Aug;56(8):2036-45. Epub 2007 May 29.PMID: 17536062 [PubMed - indexed for MEDLINE]Related articlesFree article

P633H, a novel dual agonist at peroxisome proliferator-activated receptors alpha and gamma, with different anti-diabetic effects in db/db and KK-Ay mice.

Chen W, Zhou XB, Liu HY, Xu C, Wang LL, Li S.

Br J Pharmacol. 2009 Jul;157(5):724-35. Epub 2009 May 5.PMID: 19422369 [PubMed - indexed for MEDLINE]Related articles

PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice.

Park CW, Zhang Y, Zhang X, Wu J, Chen L, Cha DR, Su D, Hwang MT, Fan X, Davis L, Striker G, Zheng F, Breyer M, Guan Y.

Kidney Int. 2006 May;69(9):1511-7.PMID: 16672921 [PubMed - indexed for MEDLINE]Related articles

Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha.

Park CW, Kim HW, Ko SH, Chung HW, Lim SW, Yang CW, Chang YS, Sugawara A, Guan Y, Breyer MD.

Diabetes. 2006 Apr;55(4):885-93.PMID: 16567507 [PubMed - indexed for MEDLINE]Related articlesFree article

Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice.

Chira EC, McMillen TS, Wang S, Haw A 3rd, O'Brien KD, Wight TN, Chait A.

Atherosclerosis. 2007 Nov;195(1):100-9. Epub 2007 Jan 9.PMID: 17214992 [PubMed - indexed for MEDLINE]Related articlesFree article

The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.

Tonstad S, Retterstøl K, Ose L, Ohman KP, Lindberg MB, Svensson M.

Metabolism. 2007 Sep;56(9):1285-92.PMID: 17697874 [PubMed - indexed for MEDLINE]Related articles

A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.

Reifel-Miller A, Otto K, Hawkins E, Barr R, Bensch WR, Bull C, Dana S, Klausing K, Martin JA, Rafaeloff-Phail R, Rafizadeh-Montrose C, Rhodes G, Robey R, Rojo I, Rungta D, Snyder D, Wilbur K, Zhang T, Zink R, Warshawsky A, Brozinick JT.

Mol Endocrinol. 2005 Jun;19(6):1593-605. Epub 2005 Apr 14.PMID: 15831517 [PubMed - indexed for MEDLINE]Related articlesFree article

Improvement of postprandial lipid handling and glucose tolerance in a non-diabetic population by the dual PPARalpha/gamma agonist, tesaglitazar.

Fagerberg B, Schuster H, Birketvedt GS, Tonstad S, Ohman KP, Gause-Nilsson I; SIR Study Group.

Diab Vasc Dis Res. 2007 Sep;4(3):174-80.PMID: 17907107 [PubMed - indexed for MEDLINE]Related articles

Therapeutic potential of peroxisome proliferators--activated receptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes.

Han KL, Choi JS, Lee JY, Song J, Joe MK, Jung MH, Hwang JK.

Diabetes. 2008 Mar;57(3):737-45. Epub 2007 Dec 7.PMID: 18065517 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial.

Goldstein BJ, Rosenstock J, Anzalone D, Tou C, Ohman KP.

Curr Med Res Opin. 2006 Dec;22(12):2575-90.PMID: 17166340 [PubMed - indexed for MEDLINE]Related articles

Tesaglitazar, a dual PPAR{alpha}/{gamma} agonist, ameliorates glucose and lipid intolerance in obese Zucker rats.

Oakes ND, Thalén P, Hultstrand T, Jacinto S, Camejo G, Wallin B, Ljung B.

Am J Physiol Regul Integr Comp Physiol. 2005 Oct;289(4):R938-46.PMID: 16183630 [PubMed - indexed for MEDLINE]Related articles

Dual PPARalpha/gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice.

Zadelaar AS, Boesten LS, Jukema JW, van Vlijmen BJ, Kooistra T, Emeis JJ, Lundholm E, Camejo G, Havekes LM.

Arterioscler Thromb Vasc Biol. 2006 Nov;26(11):2560-6. Epub 2006 Aug 24.PMID: 16931788 [PubMed - indexed for MEDLINE]Related articlesFree article

The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice.

van der Hoorn JW, Jukema JW, Havekes LM, Lundholm E, Camejo G, Rensen PC, Princen HM.

Br J Pharmacol. 2009 Apr;156(7):1067-75. Epub 2009 Feb 13.PMID: 19220285 [PubMed - indexed for MEDLINE]Related articles

Tesaglitazar: a promising approach in type 2 diabetes.

Cox SL.

Drugs Today (Barc). 2006 Mar;42(3):139-46. Review.PMID: 16628256 [PubMed - indexed for MEDLINE]Related articles

PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse.

Calkin AC, Giunti S, Jandeleit-Dahm KA, Allen TJ, Cooper ME, Thomas MC.

Nephrol Dial Transplant. 2006 Sep;21(9):2399-405. Epub 2006 May 23.PMID: 16720596 [PubMed - indexed for MEDLINE]Related articlesFree article

PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.

Kim MK, Chae YN, Son MH, Kim SH, Kim JK, Moon HS, Park CS, Bae MH, Kim E, Han T, Choi HH, Shin YA, Ahn BN, Lee CH, Lim JI, Shin CY.

Eur J Pharmacol. 2008 Oct 24;595(1-3):119-25. Epub 2008 Aug 12.PMID: 18727927 [PubMed - indexed for MEDLINE]Related articles

Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs.

Kasai S, Inoue T, Yoshitomi H, Hihara T, Matsuura F, Harada H, Shinoda M, Tanaka I.

J Pharmacol Sci. 2008 Sep;108(1):40-8. Epub 2008 Sep 6.PMID: 18776709 [PubMed - indexed for MEDLINE]Related articlesFree article

Cilostazol ameliorates metabolic abnormalities with suppression of proinflammatory markers in a db/db mouse model of type 2 diabetes via activation of peroxisome proliferator-activated receptor gamma transcription.

Park SY, Shin HK, Lee JH, Kim CD, Lee WS, Rhim BY, Hong KW.

J Pharmacol Exp Ther. 2009 May;329(2):571-9. Epub 2009 Feb 12.PMID: 19221061 [PubMed - indexed for MEDLINE]Related articles

Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice.

Verreth W, De Keyzer D, Pelat M, Verhamme P, Ganame J, Bielicki JK, Mertens A, Quarck R, Benhabilès N, Marguerie G, Mackness B, Mackness M, Ninio E, Herregods MC, Balligand JL, Holvoet P.

Circulation. 2004 Nov 16;110(20):3259-69. Epub 2004 Nov 8.PMID: 15533870 [PubMed - indexed for MEDLINE]Related articlesFree article

Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population.

Fagerberg B, Edwards S, Halmos T, Lopatynski J, Schuster H, Stender S, Stoa-Birketvedt G, Tonstad S, Halldórsdóttir S, Gause-Nilsson I.

Diabetologia. 2005 Sep;48(9):1716-25. Epub 2005 Jul 7.PMID: 16001233 [PubMed - indexed for MEDLINE]Related articles